CanSino Biologics Inc. announced updated guidelines for its Nomination Committee, aiming to standardize the process of selecting directors and senior management, improve board composition, and enhance corporate governance. The document outlines member eligibility, nomination criteria, and the Committee’s core responsibilities.

The Committee will focus on recommending criteria and procedures for identifying suitable candidates, assessing director independence, and reviewing the structure and size of the Board. The majority of members must be independent non-executive directors. The Committee’s duties also include formulating recommendations on the reappointment or succession of directors based on performance reviews.

The guidelines detail procedural steps for selecting candidates, including collecting their professional information and confirming written consent before submission to the Board. Additional provisions address meeting protocols, quorum requirements, and confidentiality obligations. The Terms of Reference become effective upon approval by the Board, with any amendments also subject to Board authorization.